Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MST1R | Q04912 | 5/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 15/20 | 0.51 |
| ▸ | KDR | P35968 | 14/20 | 0.51 |
| ▸ | IGF1R | P08069 | 12/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14704289 | 0.92 | MST1R (0.69) | MST1RMETKDRIGF1R | |
| SCHEMBL18166778 | 0.90 | MST1R (0.56) | MST1RMETKDRIGF1R | |
| SCHEMBL18166776 | 0.85 | MST1R (0.56) | MST1RMETKDRIGF1R | |
| SCHEMBL11030863 | 0.85 | MST1R (0.47) | MST1RMETKDRIGF1R | |
| SCHEMBL1161267 | 0.83 | MST1R (0.46) | MST1RMETKDRIGF1R | |
| SCHEMBL11031908 | 0.83 | MST1R (0.45) | MST1RMETKDRIGF1R | |
| SCHEMBL11029810 | 0.83 | MEN1 (0.46) | MST1RNPC1RAB9AMETKDR | |
| SCHEMBL11050470 | 0.82 | MST1R (0.47) | MST1RMETKDRIGF1R | |
| SCHEMBL11027308 | 0.82 | MET (0.70) | MST1RMETKDRIGF1R | |
| SCHEMBL14704274 | 0.82 | MST1R (1.00) | MST1RNPC1RAB9APKMMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742043-B1 | PYRIDO-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-9283225-B2 | Pyrido-pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-20140228379-A1 | Pyrido-Pyrimidine Derivatives | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228379-A1 | Pyrido-Pyrimidine Derivatives | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| WO-2013022519-A1 | PYRIDO-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228379-A1 | Pyrido-Pyrimidine Derivatives | DPYD, CDK2, CDK1 | MST1R 1952/4885NPC1 1983/4885RAB9A 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.